PREOPERATIVE DENOSUMAB THERAPY IN PATIENTS WITH GIANT CELL TUMOR OF BONE

Giant cell tumor of bone (GCTB) is a benign osteolytic with an aggressive course, affects the metaphyseal and epiphyseal areas bone. GCTB RANKL-positive tumor. Therefore, RANKL promising target for directed influence on processes resorption. Objective. To analyze world own experience denosumab using in treatment patients giant Methods. The search publications electronicsystems was carried out Google Scholar, PubMed, ScienceDirect, specialized archives journals manuscripts. In addition, 57 histologically verified without signs malignancy were included. Results. Denosumab binds inhibits RANKL, by stopping resorption inhibiting differentiation, function survival osteoclasts. Information effectiveness drug contradictory.Some researchers claim that its use preoperative period reduces amount surgical intervention likelihood recurrenceof GCTB. effect correlates duration administration. Other authors report increase percentage local recurrence next performance curettage. This explained complexity macroscopic determination boundaries changed action preparation and, accordingly, difficulty choosing reach removal during surgery. Our showed neoadjuvant therapy 120 mg 1, 8, 15, 28 days promotes formation clear tumor, compaction consequently, risk pathological fracture allows ablastic removal. Conclusions. results study isambiguous. Under conditions followed curettage proportion recurrences At significant differences measures lesions before wide resection endoprosthesis replacement administration skeleton around compaction, which ablastically remove it reduce recurrences.